Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.95 USD | -0.52% | -2.56% | +7.61% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.61% | 1.35B | |
+9.93% | 118B | |
+10.00% | 106B | |
-11.09% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.69% | 15.97B | |
+6.83% | 14.03B | |
+16.47% | 11.67B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024